Your browser doesn't support javascript.
loading
Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms.
Figueroa, Jonine D; Koutros, Stella; Colt, Joanne S; Kogevinas, Manolis; Garcia-Closas, Montserrat; Real, Francisco X; Friesen, Melissa C; Baris, Dalsu; Stewart, Patricia; Schwenn, Molly; Johnson, Alison; Karagas, Margaret R; Armenti, Karla R; Moore, Lee E; Schned, Alan; Lenz, Petra; Prokunina-Olsson, Ludmila; Banday, A Rouf; Paquin, Ashley; Ylaya, Kris; Chung, Joon-Yong; Hewitt, Stephen M; Nickerson, Michael L; Tardón, Adonina; Serra, Consol; Carrato, Alfredo; García-Closas, Reina; Lloreta, Josep; Malats, Núria; Fraumeni, Joseph F; Chanock, Stephen J; Chatterjee, Nilanjan; Rothman, Nathaniel; Silverman, Debra T.
Afiliação
  • Figueroa JD; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Koutros S; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Colt JS; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Kogevinas M; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Garcia-Closas M; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Real FX; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Friesen MC; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Baris D; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Stewart P; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Schwenn M; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Johnson A; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Karagas MR; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Armenti KR; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Moore LE; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Schned A; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Lenz P; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Prokunina-Olsson L; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Banday AR; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Paquin A; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Ylaya K; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Chung JY; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Hewitt SM; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Nickerson ML; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Tardón A; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Serra C; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Carrato A; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • García-Closas R; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Lloreta J; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Malats N; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Fraumeni JF; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Chanock SJ; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Chatterjee N; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Rothman N; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
  • Silverman DT; Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Beth
J Natl Cancer Inst ; 107(11)2015 Nov.
Article em En | MEDLINE | ID: mdl-26374428
Few studies have demonstrated gene/environment interactions in cancer research. Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P interaction ≤ .001), rs11892031 (UGT1A, P interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P interaction = .03). There was limited evidence for multiplicative interactions. When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, P interaction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression. All statistical tests were two-sided. The interaction we observed for rs798766 (TMEM129-TACC3-FGFR3) with specific exposure to straight metalworking fluids illustrates the value of integrating germline genetic variation, environmental exposures, and tumor marker data to provide insight into the mechanisms of bladder carcinogenesis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Exposição Ocupacional / Polimorfismo de Nucleotídeo Único / Interação Gene-Ambiente / Doenças Profissionais Tipo de estudo: Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Exposição Ocupacional / Polimorfismo de Nucleotídeo Único / Interação Gene-Ambiente / Doenças Profissionais Tipo de estudo: Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2015 Tipo de documento: Article